

# The KCNT1 Epilepsy Foundation Announces Strategic Addition to Board of Directors Amid Growing Momentum in KCNT1 Research

*KCNT1 Epilepsy Foundation appoints Dr. Dewey McLin to board, bringing rare epilepsy expertise as momentum builds in KCNT1 therapy development.*

SCOTTSDALE, AZ, UNITED STATES, April 17, 2025 /EINPresswire.com/ -- The [KCNT1](#) Slack Epilepsy

“

His experience in rare epilepsy therapies will help guide our strategy during a critical time for KCNT1 research.”

*Dr. Justin West, Co-Founder*

Foundation Inc, a nonprofit dedicated to advocacy, awareness, and accelerating treatments for children living with KCNT1-related disorders, is proud to announce the appointment of Dr. Dewey McLin III to its Board of Directors.

Dr. McLin brings over two decades of leadership in Medical Affairs, with a specialized focus on rare and catastrophic neurological disorders, including his role in the successful

launch of an FDA-approved plant-derived cannabinoid for childhood-onset epilepsy. His background spans from early development to commercialization in both startup and established pharmaceutical companies, uniquely aligning with our organization’s mission during a pivotal moment in KCNT1 therapeutic development.

“We’re honored to welcome Dr. McLin to our board,” said co-founder, Dr Justin West. “His experience launching therapies in the rare epilepsy space — including his recent work at Longboard Pharma supporting clinical development for DEE-focused treatments — brings a depth of strategic and medical insight at a time when the KCNT1 field is accelerating. As several companies prepare IND submissions for KCNT1-targeted therapies, Dewey’s expertise will help shape our advocacy, partnerships, and long-term direction.”

Dr. McLin joins a dedicated board that includes other pharmaceutical leaders, parent advocates, and experts united by a shared commitment to changing the future for children affected by KCNT1-related disorders.

“I’m excited to join such a passionate and mission-driven organization,” said Dr. McLin. “Having supported families impacted by rare epilepsies in my past roles, I’m deeply committed to helping

bridge science and strategy as this community enters a promising new chapter.”

To learn more about the KCNT1 Epilepsy Foundation, its mission, or ongoing initiatives in KCNT1-related research, please visit <https://kcnt1epilepsy.org>

Sarah Drislane  
KCNT1 SLACK EPILEPSY FOUNDATION Inc  
+1 949-268-9770  
[email us here](#)



Dewey McLin, PhD Joins KCNT1 Epilepsy Foundation Board of Directors

---

This press release can be viewed online at: <https://www.einpresswire.com/article/803695173>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.